IP Library Granted Patent US 9,562,217
Granted Patent B2
US 9,562,217 · App. 13/858,354 · Granted Feb 7, 2017

Modalities for the treatment of degenerative diseases of the retina

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,562,217
App. No.
13/858,354
Granted
Feb 7, 2017
Kind
B2
Abstract

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

Claims (6)

1. A composition comprising isolated human RPE cells obtained by in vitro differentiation of human pluripotent cells that express Oct-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-I-60, and TRA-I-81, wherein said human RPE cells express RPE65 and bestrophin and wherein said composition is suitable for transplantation or injection into a human patient in need thereof.

2. A composition of claim 1 wherein the human RPE cells are present in a monolayer.

3. A frozen preparation of human RPE cells obtained by in vitro differentiation of human pluripotent cells that express Oct-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-I-60, and TRA-I-81, which frozen human RPE cells upon thawing are suitable for use in treating a human patient.

4. The composition or preparation of claim 1 or 3 , wherein said human RPE cells express CRALBP, PEDF, RPE65 and bestrophin.

5. The composition or preparation of claim 1 or 3 , which comprises human RPE cells that exhibit a cobblestone, epithelial-like, polygonal appearance.

6. The composition or preparation of claim 1 or 3 , which comprises human RPE cells that express CRALBP, PEDF, RPE65 and bestrophin and exhibit a cobblestone, epithelial-like, polygonal appearance.

Assignments (5)
CONFIRMATORY ASSIGNMENT Recorded Apr 5, 2024
From: ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 067024/0057 →
CHANGE OF NAME Recorded Jul 27, 2016
From: OCATA THERAPEUTICS, INC.
To: ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
Reel/Frame 039493/0166 →
CHANGE OF NAME Recorded Feb 13, 2015
From: ADVANCED CELL TECHNOLOGY, INC.
To: OCATA THERAPEUTICS, INC.
Reel/Frame 034999/0826 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2014
From: KLIMANSKAYA, IRINA V.
To: ADVANCED CELL TECHNOLOGY, INC.
Reel/Frame 034023/0115 →
CONFIRMATORY ASSIGNMENT Recorded Oct 23, 2014
From: LANZA, ROBERT
To: ADVANCED CELL TECHNOLOGY, INC.
Reel/Frame 034038/0172 →